09969.HK_Providing professional financial news and data related to 09969.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

INNOCARE (09969.HK): Phase III Trial of Fadeucravacitinib (ICP-488) for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint

Tags：

INNOCARE 09969.HK Clinical Trial primary endpoint

2026-07-27

INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline

Tags：

INNOCARE 09969.HK Clinical Trial

2026-07-16

InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully

Tags：

InnoCare Pharma Limited 09969.HK

2026-07-15

INNOCARE(09969.HK): NDA of Orelabrutinib for ITP Accepted by NMPA

Tags：

INNOCARE 09969.HK New Drug Marketing Application

2026-05-28

INNOCARE(09969.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 105.82 million, YoY increase of 488.93%

Tags：

INNOCARE 09969.HK financials

2026-04-24

Scan QR Code

Download App